-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Qilu Pharmaceutical has entered the administrative approval stage for the production of generic oseltamivir phosphate capsules of Category 4, and is expected to be approved for marketing in the near future
.
Oseltamivir is a classic anti-influenza drug with terminal sales of over 2.
7 billion yuan in Chinese public medical institutions in 2020
.
.
Oseltamivir is a classic anti-influenza drug with terminal sales of over 2.
7 billion yuan in Chinese public medical institutions in 2020
.
Oseltamivir phosphate is a potent and selective inhibitor of influenza virus neuraminidase, mainly used for the prevention and treatment of influenza A and
B.
At present, oseltamivir products that have been marketed in China include capsules, granules, and dry suspensions
.
B.
At present, oseltamivir products that have been marketed in China include capsules, granules, and dry suspensions
.
According to data from Minet.
com, in 2020, the sales of terminal oseltamivir in China's urban public hospitals
, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 2.
7 billion yuan .
com, in 2020, the sales of terminal oseltamivir in China's urban public hospitals
, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 2.
7 billion yuan .
Sales of terminal oseltamivir in Chinese public medical institutions (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
In the seventh batch of centralized collection and report volume catalog, oseltamivir oral normal-release dosage form is listed impressively
.
.
In addition to the original manufacturer Roche, there are 7 domestic companies that have production approvals for oseltamivir phosphate capsules, including Sunshine Pharmaceuticals, Borui Pharmaceuticals, Shanghai Pharmaceuticals Chinese and Western Pharmaceuticals, CSPC, Kelun Pharmaceuticals, Beite Pharmaceuticals,
etc.
At present, the products of these 7 companies have passed/deemed to pass the consistency evaluation
.
etc.
At present, the products of these 7 companies have passed/deemed to pass the consistency evaluation
.
It is worth noting that there are more than 10 companies whose listing applications for oseltamivir phosphate capsules are under review
.
The registration status of Qilu Pharmaceutical's Oseltamivir Phosphate Capsules has been changed to "under approval"
.
.
The registration status of Qilu Pharmaceutical's Oseltamivir Phosphate Capsules has been changed to "under approval"
.
Data source: Minet database, NMPA
Recently, Qilu Pharmaceutical has entered the administrative approval stage for the production of generic oseltamivir phosphate capsules of Category 4, and is expected to be approved for marketing in the near future
.
Oseltamivir is a classic anti-influenza drug with terminal sales of over 2.
7 billion yuan in Chinese public medical institutions in 2020
.
.
Oseltamivir is a classic anti-influenza drug with terminal sales of over 2.
7 billion yuan in Chinese public medical institutions in 2020
.
Oseltamivir phosphate is a potent and selective inhibitor of influenza virus neuraminidase, mainly used for the prevention and treatment of influenza A and
B.
At present, oseltamivir products that have been marketed in China include capsules, granules, and dry suspensions
.
B.
At present, oseltamivir products that have been marketed in China include capsules, granules, and dry suspensions
.
According to data from Minet.
com, in 2020, the sales of terminal oseltamivir in China's urban public hospitals
, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 2.
7 billion yuan .
com, in 2020, the sales of terminal oseltamivir in China's urban public hospitals
, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 2.
7 billion yuan .
Sales of terminal oseltamivir in Chinese public medical institutions (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
In the seventh batch of centralized collection and report volume catalog, oseltamivir oral normal-release dosage form is listed impressively
.
.
In addition to the original manufacturer Roche, there are 7 domestic companies that have production approvals for oseltamivir phosphate capsules, including Sunshine Pharmaceuticals, Borui Pharmaceuticals, Shanghai Pharmaceuticals Chinese and Western Pharmaceuticals, CSPC, Kelun Pharmaceuticals, Beite Pharmaceuticals,
etc.
At present, the products of these 7 companies have passed/deemed to pass the consistency evaluation
.
etc.
At present, the products of these 7 companies have passed/deemed to pass the consistency evaluation
.
It is worth noting that there are more than 10 companies whose listing applications for oseltamivir phosphate capsules are under review
.
The registration status of Qilu Pharmaceutical's Oseltamivir Phosphate Capsules has been changed to "under approval"
.
.
The registration status of Qilu Pharmaceutical's Oseltamivir Phosphate Capsules has been changed to "under approval"
.
Data source: Minet database, NMPA
Recently, Qilu Pharmaceutical has entered the administrative approval stage for the production of generic oseltamivir phosphate capsules of Category 4, and is expected to be approved for marketing in the near future
.
Oseltamivir is a classic anti-influenza drug with terminal sales of over 2.
7 billion yuan in Chinese public medical institutions in 2020
.
.
Oseltamivir is a classic anti-influenza drug with terminal sales of over 2.
7 billion yuan in Chinese public medical institutions in 2020
.
Oseltamivir phosphate is a potent and selective inhibitor of influenza virus neuraminidase, mainly used for the prevention and treatment of influenza A and
B.
At present, oseltamivir products that have been marketed in China include capsules, granules, and dry suspensions
.
B.
At present, oseltamivir products that have been marketed in China include capsules, granules, and dry suspensions
.
According to data from Minet.
com, in 2020, the sales of terminal oseltamivir in China's urban public hospitals
, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 2.
7 billion yuan .
hospital hospital hospitalcom, in 2020, the sales of terminal oseltamivir in China's urban public hospitals
, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 2.
7 billion yuan .
Sales of terminal oseltamivir in Chinese public medical institutions (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
In the seventh batch of centralized collection and report volume catalog, oseltamivir oral normal-release dosage form is listed impressively
.
.
In addition to the original manufacturer Roche, there are 7 domestic companies that have production approvals for oseltamivir phosphate capsules, including Sunshine Pharmaceuticals, Borui Pharmaceuticals, Shanghai Pharmaceuticals Chinese and Western Pharmaceuticals, CSPC, Kelun Pharmaceuticals, Beite Pharmaceuticals,
etc.
At present, the products of these 7 companies have passed/deemed to pass the consistency evaluation
.
enterprise enterprise enterpriseetc.
At present, the products of these 7 companies have passed/deemed to pass the consistency evaluation
.
It is worth noting that there are more than 10 companies whose listing applications for oseltamivir phosphate capsules are under review
.
The registration status of Qilu Pharmaceutical's Oseltamivir Phosphate Capsules has been changed to "under approval"
.
.
The registration status of Qilu Pharmaceutical's Oseltamivir Phosphate Capsules has been changed to "under approval"
.
Data source: Minet database, NMPA
